Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2016 by Polyphor Ltd.
Information provided by (Responsible Party):
Polyphor Ltd. Identifier:
First received: April 2, 2013
Last updated: August 31, 2016
Last verified: August 2016
POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin. Different doses and dosing frequencies will be investigated

Condition Intervention Phase
Metastatic Breast Cancer
Drug: POL6326
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Dose Escalation Study of POL6326 With Eribulin in Patients With Relapsed, Triple Negative and Hormone Refractory ER Positive Metastatic Breast Cancer

Resource links provided by NLM:

Further study details as provided by Polyphor Ltd.:

Primary Outcome Measures:
  • Safety and tolerability of POL6326 in combination with eribulin in patients with metastatic breast cancer [ Time Frame: 6 months ]
    Incidence and severity of adverse events and serious adverse events of the combination of POL6326 and eribulin when compared to the adverse event profile of eribulin alone

Secondary Outcome Measures:
  • Response rate of treatment with POL6326 and eribulin in patients with metastatic breast cancer [ Time Frame: 12-24 months ]
    Determination of the complete response (CR) and partial response (PR) in patients treated with the combination of POL6326 and eribulin

Estimated Enrollment: 48
Study Start Date: June 2013
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: POL6326
POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin
Drug: POL6326
POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed invasive cancer of the breast.
  • Presence of at least one measurable lesion per RECIST 1.1 criteria
  • Stage IV disease by AJCC criteria (7th edition).
  • HER2 negative (IHC 0,1 or FISH HER2:CEP17 ratio < 2.0)
  • Must have had treatment with at least 2 but no more than 3 previous regimens in the metastatic setting. Previous treatment must have included an anthracycline and taxane in either the adjuvant or metastatic setting.
  • At least 21 days from the completion of any previous cytotoxic chemotherapy or biological therapy at time of initiation of POL6326.
  • ECOG performance status < 2

Exclusion Criteria:

  • Previously received eribulin.
  • Peripheral neuropathy > Grade 2.
  • Receipt of any other investigational agent within the 28 days prior to Day 1.
  • Receipt of colony stimulating factor filgrastim, pegfilgrastim, or sargramostim within 14 days prior to Day 1.
  • Radiation therapy within the 14 days prior to Day 1.
  • Severe concurrent illness or psychiatric illness/social situation that would limit compliance with study requirements.
  • History of other malignancy ≤ 5 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or carcinoma in situ of the cervix.
  • Pregnant or breastfeeding.
  • Known HIV positivity on combination antiretroviral therapy; these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01837095

Contact: Javier Cortès Castan, M.D.

United States, Kansas
St Luke's Cancer Institute Not yet recruiting
Kansas City, Kansas, United States, 64111
United States, Missouri
Washington University School of Medicine, Division of Oncology Active, not recruiting
St. Louis, Missouri, United States, 63110
United States, New Hampshire
'Dartmouth-Hitchcock Medical Center Recruiting
Lebanon, New Hampshire, United States, 03756
United States, New York
Weill Cornell Breast Center Recruiting
New-York, New York, United States, 10065
United States, Tennessee
Vanderbilt University School of Medicine Recruiting
Nashville, Tennessee, United States, 37232
Hospital del Mar Recruiting
Barcelona, Spain, 08003
Hospital Quiron Barcelona Recruiting
Barcelona, Spain, 08023
Hospital Vall d'Hebrón Recruiting
Barcelona, Spain, 08035
Instituto Catalàn de Oncologia L'Hospitalet Recruiting
L'Hospitalet de Llobregat, Spain, 08908
HGUG Marañón Recruiting
Madrid, Spain, 28007
Hospital 12 de Octubre Recruiting
Madrid, Spain, 28041
Hospital Cinico Universitario de ValenciaValencia Recruiting
Valencia, Spain, 46010
Sponsors and Collaborators
Polyphor Ltd.
  More Information

Responsible Party: Polyphor Ltd. Identifier: NCT01837095     History of Changes
Other Study ID Numbers: POL-7 
Study First Received: April 2, 2013
Last Updated: August 31, 2016

Keywords provided by Polyphor Ltd.:
Overall survival
Progression free survival

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases processed this record on January 19, 2017